Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson To Acquire Schein: Generic Business Projected At $800 Mil. In 2001

Executive Summary

Watson expects its generic drug business to top $800 mil. in revenues during 2001 after it completes the proposed acquisition of Schein.

You may also be interested in...



Watson Moves Reps To Women's, General Divisions For Branded Launches

Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.

Watson Moves Reps To Women's, General Divisions For Branded Launches

Watson Pharmaceuticals is shifting sales reps from its dermatology division to support product launches in its general products and women's health divisions.

Watson

Investment banking firm CIBC World Markets is retained to assist in the evaluation of possible alternatives, including possible divestiture, for its two sterile injectable manufacturing facilities in Phoenix, Ariz. and Cherry Hill, N.J. Watson acquired the facilities through its recent acquisition of Schein, completed Aug. 28 (1"The Pink Sheet" May 29, p. 27). Watson said it will continue to market the injectable products INFeD and Ferrlecit. Although INFeD is manufactured at the Phoenix facility, Watson will consider a contract manufacturing arrangement for the product. Watson also names former Schein Senior VP-Quality Donald Britt as Senior VP-corporate quality assurance

Related Content

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel